Terns Pharmaceuticals: A Rising Star in the Pharmaceutical Industry
The pharmaceutical industry has long been a focal point of investors, with some of the most pressing health concerns around the world demanding novel solutions that can only be provided by these companies. One such organization that has attracted significant attention is Terns Pharmaceuticals, Inc., which reportedly boasts an average rating of “Moderate Buy” among seven analysts currently providing coverage from Bloomberg.com.
Of these analysts, five have issued a buy recommendation for the stock while two have taken a more conservative approach with a hold recommendation. However, what is perhaps most notable is the $15.86 average price target over the next year among those who updated their coverage within the past year.
This data reflects growing optimism around Terns Pharmaceuticals and its potential to drive innovation in this space, despite being a fairly recent entrant with its founding in 2017. The company has already made waves by reporting positive earnings results for Q1 2021, topping consensus estimates by $0.11 with an EPS of ($0.29). This marked a significant milestone for Terns as it continues to gain traction amongst investors looking for high-growth opportunities.
Despite its youthfulness relative to other pharmaceutical giants, Terns Pharmaceuticals’ leadership team brings decades of experience from top-tier organizations within and beyond pharma. From former senior vice presidents at Pfizer and Roche to chief medical officers at Karyopharm Therapeutics, Terns is demonstrating an aptitude for attracting and retaining talent from across industries.
With current expectations suggesting that Terns will post -1.28 EPS in the current fiscal year, this nascent company stands poised to break into the upper echelons of biotech firms- promising new drug pipelines and innovative therapies that could transform lives across borders.
In conclusion, while some may remain reticent about investing in emerging firms like Terns Pharmaceuticals due to perceived risks or lack of pedigree compared to pharmaceutical incumbents; these newly minted organizations represent some of the most fertile ground for disruption and innovation in a high-growth industry that’s forever changing. Therefore, patients, investors and other stakeholders alike should all keep abreast of developments as this space continues to evolve – with corporations like Terns Pharmaceuticals bringing the buzz of fresh ideas through groundbreaking therapeutic approaches.
TERN
Neutral
Updated on: 03/06/2023
Price Target
Show more
Social Sentiments
We did not find social sentiment data for this stock
Analyst Ratings
| Analyst / firm | Rating |
|---|---|
| H.C. Wainwright | Sell |
| Goldman Sachs | Buy |
|
Corinne Jenkins Goldman Sachs |
Sell |
Show more
Analysts offer diverse ratings for Terns Pharmaceuticals: A closer look into the company’s stock analysis
In the fast-paced world of stock market analysis, where different opinions about a company’s potential to grow and succeed are always arising, it is crucial to have various options before making any investment decisions. Recently, several equities analysts published their reports on Terns Pharmaceuticals (NASDAQ:TERN), with diverse ratings for the company.
UBS Group started coverage on Terns Pharmaceuticals on February 7th, setting a “buy” rating and a $19.00 price objective. Meanwhile, BMO Capital Markets assigned an “outperform” rating and a $18.00 target price for the biotech firm, according to their report released on May 8th.
HC Wainwright gave shares of Terns Pharmaceuticals a “neutral” rating with a $11.00 target price in another research report published on March 29th; however , they lifted the target price from $7.00 previously set. JPMorgan Chase & Co., for its part, increased the price objective of Terns Pharmaceuticals from $6.00 to $9.00 and designated it as “neutral.” Lastly, Roth Mkm also initiated coverage with buy ratings and issued a higher target of $23.00 per share.
Despite these positive ratings from reputable analysts for Terns Pharmaceuticals shares, investors continued cautiously in trading as the market opened on Friday morning (June 25th). The pharmaceutical firm’s shares were valued at $11.30 each amid uncertain stock markets globally.
The company boasts a solid high-low range balance – which recently hit its highest peak at a whopping $14.04 per share while maintaining its low-end support at $1.60 over the past year – indicating that buyers have not been backing off despite any previous volatility or hiccups along the way.
Furthermore, Tern’s fifty day moving average estimates its stock value at around $11.80 per share which is notably favorable compared to the current trading price, and the 200 day moving average rests at $9.61 per share. With a market cap of almost $640.37 million, it is evident that investors see something unique in Terns Pharmaceuticals’ growth story.
In conclusion, Terns Pharmaceuticals continues to enjoy bullish sentiments from leading equity analysts despite its current trading status within the tight range of $11.30 to $11.80 per share. Market watchers project that with increasing investor confidence and development of new therapies by Tern’s innovative product pipeline, the company will prosper even further down the road, proving itself as a worthy contender in the pharmaceutical industry.
No Byline Policy
Editorial Guidelines
Corrections Policy
Source